Oropharyngeal Administration of Mother's Colostrum for Premature Infants (NS-72393-360)

Completed · Not applicable

Conditions studied: Infection, Enterocolitis, Necrotizing, Ventilator-associated Pneumonia

In brief

Extremely premature (BW\<1250g) infants are at high risk for morbidity and mortality. Own mother's colostrum (OMC) and milk (OMM) protect against neonatal morbidity and are rich in immune factors which may provide immunostimulatory effects when administered oropharyngeally to extremely premature infants during the first weeks of life. The investigators hypothesize that infants who receive oropharyngeal mother's colostrum and milk will have significantly lower rates of infection and improved health outcomes, compared to infants who receive a placebo.

Key facts

Study ID
NCT02116699
Run by
Endeavor Health
People needed
260
Starts
2013-11-20
Expected to finish
2022-01-04
Last updated by the study team
2023-03-01

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.